• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Abbott (ABT) Stock May Be 25% Stretched After Biosensor Market Forecast

    Simply Wall St·09/30/2026 20:27:26
    Listen to the news

    Abbott Laboratories has seen its share price retreat over the past year, which puts the spotlight squarely on whether the current market value lines up with the cash the business is expected to generate. For investors already holding Abbott stock or thinking about starting a position, the question now is how well the recent share price reflects those cash flows.

    • The share price has fallen 22.9% over the past year, which raises the issue of whether the recent slide has brought the valuation closer to what Abbott's stream of cash flows can support.
    • New growth avenues in areas such as wearable biosensors and therapeutic drug monitoring can influence expectations for future revenue and free cash generation, which feeds directly into any cash flow based estimate of what the business might be worth today.
    • If you'd rather focus on earnings, this one's for you. See why Abbott Laboratories's 32.3x P/E tells a different valuation story.

    The stock's next move may depend on whether Abbott Laboratories' current price is well aligned with what a Discounted Cash Flow (DCF) view of its future cash flows implies.

    If you want to test the same cash flow question on a wider set of companies beyond Abbott Laboratories, take a look at 32 high quality undervalued stocks.

    Does Abbott Laboratories Look Pricey on Cash Flow?

    The Discounted Cash Flow (DCF) approach values Abbott Laboratories by projecting its future free cash generation and discounting it back to today. Over the latest twelve months, Abbott produced about $7.6b of free cash flow, and the DCF framework assumes this cash output continues but with a gently declining profile over the next decade rather than rapid expansion.

    Those softer long term assumptions mean the DCF model still puts the estimated intrinsic value meaningfully below the current share price of $100.95. The forecast growth in wearable biosensors highlighted in recent market reports gives Abbott Laboratories more opportunities to monetise its technology, yet the current projections in the cash flow model do not treat that potential as a strong accelerator of future free cash flow. That gap between what the DCF implies and where the stock trades is what the detailed valuation output is designed to clarify. Find out what Abbott Laboratories could be worth using our Discounted Cash Flow (DCF) estimate.

    The Abbott Laboratories Narrative: What Would Justify Today's Price?

    Narratives on Abbott Laboratories pick up where the DCF puzzle leaves off by spelling out which paths for growth, profitability and earnings would need to play out for the stock to be worth materially more or less than today’s quote, and they sit on Simply Wall St’s Community page. Instead of a single number from a model or ratio, they lay out the future that number relies on so you can follow whether those conditions are actually emerging.

    One of the top community narratives on Abbott Laboratories: 16% undervalued

    "The main thing that has to go right is that Abbott Laboratories continues to convert its medical technology pipeline into sustained sales growth and margin expansion…"

    Discover why this Narrative puts Abbott Laboratories at 16% undervalued.

    Before you act on Abbott Laboratories' valuation, there is one more angle to check

    Abbott Laboratories' pricing story is only part of the picture, because Simply Wall St's broader review has also flagged specific issues that investors may want to weigh carefully before making any move. Take a closer look at 2 warning signs before settling on a valuation.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.